Please assess the completion status of the following clinical trial:

Trial Title: An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* This study will only include participants who were enrolled in the FIGARO-DKD study (NCT02545049) and had received up to 20 mg finerenone or placebo for ≥24 months.~* For each participant, pharmacokinetic (PK) plasma samples from Visit 3 and at least 2 other Visits (Visit 5, Visit 8, Visit 11) must be available on storage from the main study FIGARO-DKD.~Exclusion Criteria:~* Participants which did not show overall compliance of 80 to 120% with study intervention in FIGARO-DKD.~* Participants which were not part of the full analysis set (FAS) of FIGARO-DKD.~* Participants with known fatal outcome.~* Participants with baseline estimated glomerular filtration rate (eGFR) ≤25 mL/min/1.73m\^2.~* Participants with low baseline risk (normal albuminuria and eGFR≥60 mL/min/1.73m\^2).~* Sponsor request (after discussion with the investigator), for reasons such as a significant protocol deviation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Finerenone (Type: EXPERIMENTAL): Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.

Based on this trial design, predict the completion outcome and termination type (if applicable).